DISCOVERY OF NOVEL MOLECULAR TARGETS FOR ENDOGENOUS AND SYNTHETIC CANNABINOIDS

内源性和合成大麻素的新分子靶标的发现

基本信息

项目摘要

The neurotransmitter, dopamine, modulates excitatory and inhibitory neurotransmission in brain regions that control movement, emotion, and reward. Dysregulation of DA transmission is implicated in the etiology of several pathological conditions including Parkinsons disease, drug addiction, and schizophrenia. The dopamine transporter (DAT) is an integral membrane protein that is a member of the Na+- and Cl-- dependent cotransporter gene family. It serves a key role in terminating dopamine transmission by clearing dopamine released into the extracellular space. Systemic administration of the endocannabinoid, anandamide, increases extracellular dopamine concentrations in the nucleus accumbens, a brain region implicated in mediating the abuse liability of various psychoactive drugs. Increased dopamine concentrations are also observed in response to synthetic cannabinoid agonists. Although these effects have been attributed to alterations in release, evidence that anandamide and other cannabinoids inhibit transporter-mediated dopamine uptake in native tissue and heterologous expression systems has been presented. Such findings are noteworthy in that they suggest that endocannabinoids may modulate dopamine transmission by regulating DAT function. The cellular mechanisms mediating the interaction of anandamide with DAT are unclear. Although there is evidence that it may modulate DAT function by a CB1 independent mechanism, whether the effect of anandamide is mediated by the activation of other cannabinoid receptors such as CB2 and GPR55 that are expressed in the brain is unclear. In addition, although prolonged incubation of cells or synaptosomes decreases dopamine uptake, the time course and the cellular mechanisms of this effect have not been assessed. We previously demonstrated that use of the fluorescent, high affinity DAT substrate, ASP+ 4-(4-(dimethylamino)styrl)-N-methylpyridinium))in combination with confocal microscopy enables real-time, spatially resolved analysis of transporter function in heterologous expression systems. Analysis of ASP+ accumulation not only permits resolution of substrate binding and uptake in the same cell but enables quantification of rapid (e.g. 1 min) changes in DAT function (see: Bolan et al., 2007, Zapata et al 2007). Using this technique we have investigated the effect of anandamide on the function of human DAT (hDAT) expressed in the EM4 HEK 293 cell line which does not endogenously express known cannabinoid receptors. In parallel studies, biochemical and confocal imaging techniques were employed to assess the role of transporter trafficking in mediating anandamide-evoked alterations in DAT function. Addition of anandamide to EM4 cells transiently transfected to express fluorescently tagged hDAT produced a concentration-dependent inhibition of ASP+ accumulation. This effect was rapid occurring within 1 min after anandomide addition. Increased DAT function was long-lasting. A significant inhihibition of ASP+ accumulation was still apparent 10 min after anandamide addition. Incubation of cells with pertussis toxin did not attenuate the effects of anandamide suggesting a mechanism independent of Gi/Go coupled receptors. The amidohydrolase inhibitor, phenylmethylsulfonyl fluoride, failed to alter the effects of anandomide. No change in ASP+ accumulation was observed in response to arachidonic acid suggesting that the effects of anandamide are not mediated by its metabolic products. The downregulation of DAT function was associated with a significant redistribution of hDAT from the membrane to the cytosol as measured using both confocal microscopy and biotinylation techniques. These results demonstrate that anandamide modulates DAT function via a cannabinoid receptor-independent mechanism. Furthermore, they suggest that endocannabinoids may increase extracellular dopamine, in part, by increasing DAT internalization.
神经递质多巴胺调节控制运动、情绪和奖励的大脑区域的兴奋性和抑制性神经传递。 DA 传输失调与多种病理状况的病因有关,包括帕金森病、药物成瘾和精神分裂症。多巴胺转运蛋白 (DAT) 是一种完整的膜蛋白,是 Na+- 和 Cl- 依赖性协同转运蛋白基因家族的成员。它通过清除释放到细胞外空间的多巴胺来终止多巴胺传输。全身施用内源性大麻素 anandamide 会增加伏隔核中细胞外多巴胺的浓度,伏隔核是一个与介导各种精神活性药物滥用倾向有关的大脑区域。还观察到合成大麻素激动剂引起的多巴胺浓度增加。尽管这些效应归因于释放的改变,但已有证据表明大麻素和其他大麻素抑制天然组织和异源表达系统中转运蛋白介导的多巴胺摄取。这些发现值得注意,因为它们表明内源性大麻素可能通过调节 DAT 功能来调节多巴胺的传递。介导 anandamide 与 DAT 相互作用的细胞机制尚不清楚。尽管有证据表明它可能通过 CB1 独立机制调节 DAT 功能,但 anandamide 的作用是否是通过激活大脑中表达的 CB2 和 GPR55 等其他大麻素受体介导的。此外,虽然细胞或突触体的长时间孵育会减少多巴胺的摄取,但这种效应的时间过程和细胞机制尚未得到评估。我们之前证明,使用荧光高亲和力 DAT 底物 ASP+ 4-(4-(二甲氨基)苯乙烯)-N-甲基吡啶鎓))与共焦显微镜相结合,可以对异源表达中的转运蛋白功能进行实时、空间分辨分析系统。 ASP+ 积累的分析不仅可以解析同一细胞中的底物结合和摄取,还可以量化 DAT 功能的快速(例如 1 分钟)变化(参见:Bolan 等人,2007 年;Zapata 等人,2007 年)。使用这项技术,我们研究了 anandamide 对 EM4 HEK 293 细胞系中表达的人 DAT (hDAT) 功能的影响,该细胞系不内源表达已知的大麻素受体。在平行研究中,采用生化和共聚焦成像技术来评估转运蛋白运输在介导 anandamide 引起的 DAT 功能改变中的作用。向瞬时转染表达荧光标记 hDAT 的 EM4 细胞中添加 anandamide 会产生浓度依赖性的 ASP+ 积累抑制。添加 anandomide 后 1 分钟内,该效果迅速发生。 DAT 功能的增强是持久的。添加 anandamide 10 分钟后,对 ASP+ 积累的显着抑制仍然很明显。 细胞与百日咳毒素一起孵育并没有减弱 anandamide 的作用,表明其机制不依赖于 Gi/Go 偶联受体。酰胺水解酶抑制剂苯甲基磺酰氟未能改变阿那度胺的作用。没有观察到花生四烯酸对 ASP+ 积累的影响,这表明花生四烯酸的作用不是由其代谢产物介导的。使用共聚焦显微镜和生物素化技术测量,DAT 功能的下调与 hDAT 从膜到细胞质的显着重新分布相关。这些结果表明 anandamide 通过大麻素受体独立机制调节 DAT 功能。此外,他们认为内源性大麻素可能部分通过增加 DAT 内化来增加细胞外多巴胺。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Toni Shippenberg其他文献

Toni Shippenberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Toni Shippenberg', 18)}}的其他基金

Neurobiology of Psychostimulant and Opiate Addiction
精神兴奋剂和阿片成瘾的神经生物学
  • 批准号:
    7966914
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
Descending Modulation of Nerve Injury and Injury-Evoked Pain
神经损伤和损伤引起的疼痛的降序调节
  • 批准号:
    7966916
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
Neurobiology of Psychostimulant and Opiate Addiction
精神兴奋剂和阿片成瘾的神经生物学
  • 批准号:
    8336484
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
DISCOVERY OF NOVEL MOLECULAR TARGETS FOR ENDOGENOUS AND SYNTHETIC CANNABINOIDS
内源性和合成大麻素的新分子靶标的发现
  • 批准号:
    7593315
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
Neurobiology of Alcohol and Inhalant Abuse
酒精和吸入滥用的神经生物学
  • 批准号:
    7733833
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
Neurobiology of Alcohol and Inhalant Abuse
酒精和吸入滥用的神经生物学
  • 批准号:
    8336461
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
DISCOVERY OF NOVEL MOLECULAR TARGETS FOR ENDOGENOUS AND SYNTHETIC CANNABINOIDS
内源性和合成大麻素的新分子靶标的发现
  • 批准号:
    7733842
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
Descending Modulation of Nerve Injury and Injury-Evoked Pain
神经损伤和损伤引起的疼痛的降序调节
  • 批准号:
    8336485
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
Modeling Goal-Oriented Versus Habitual Drug-Seeking and Taking In Rodents
模拟目标导向型与习惯性寻求药物和收容啮齿类动物
  • 批准号:
    8336501
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:
Neurobiology of Psychostimulant and Opiate Addiction
精神兴奋剂和阿片成瘾的神经生物学
  • 批准号:
    7593307
  • 财政年份:
  • 资助金额:
    $ 11.79万
  • 项目类别:

相似国自然基金

乙酰胆碱通过a7nAChR调控巨噬细胞极化对肩袖损伤愈合的影响及相关机制研究
  • 批准号:
    82102580
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
neuregulin1通过agrin/Lrp4/MuSK信号通路影响面肌和骨骼肌对肌松药敏感性差异的机制研究
  • 批准号:
    81870714
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
基底前脑对听觉稳态反应的影响及其在精神分裂症听觉功能异常中的作用
  • 批准号:
    31671080
  • 批准年份:
    2016
  • 资助金额:
    62.0 万元
  • 项目类别:
    面上项目
胆碱能抗炎通路对脓毒症血小板活化及炎性反应的影响
  • 批准号:
    81571946
  • 批准年份:
    2015
  • 资助金额:
    52.0 万元
  • 项目类别:
    面上项目

相似海外基金

Regulation of Basal Endocannabinoid Tone in the Hippocampus
海马基础内源性大麻素张力的调节
  • 批准号:
    8133446
  • 财政年份:
    2010
  • 资助金额:
    $ 11.79万
  • 项目类别:
Regulation of Basal Endocannabinoid Tone in the Hippocampus
海马基础内源性大麻素张力的调节
  • 批准号:
    7991934
  • 财政年份:
    2010
  • 资助金额:
    $ 11.79万
  • 项目类别:
Regulation of Basal Endocannabinoid Tone in the Hippocampus
海马基础内源性大麻素张力的调节
  • 批准号:
    8531114
  • 财政年份:
    2010
  • 资助金额:
    $ 11.79万
  • 项目类别:
Regulation of Basal Endocannabinoid Tone in the Hippocampus
海马基础内源性大麻素张力的调节
  • 批准号:
    8318727
  • 财政年份:
    2010
  • 资助金额:
    $ 11.79万
  • 项目类别:
Regulation of Basal Endocannabinoid Tone in the Hippocampus
海马基础内源性大麻素张力的调节
  • 批准号:
    8721293
  • 财政年份:
    2010
  • 资助金额:
    $ 11.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了